Key points from article :
Inbrain Neuroelectronics, a neurotech company from Barcelona, is making waves in brain-computer interface (BCI) technology with its graphene-based platform. Recently, the company secured $50 million in Series B funding, which will fuel its efforts to advance treatments for neurological diseases like Parkinson’s. This funding will also support ongoing clinical trials, team expansion, and the enhancement of Inbrain’s AI-driven capabilities to improve patient outcomes through highly tailored treatments. To further drive its mission, Inbrain has partnered with Merck to boost the clinical development of its BCI technology for both central and peripheral nervous system applications.
Inbrain’s technology stands out due to its use of graphene—a super-strong, flexible, and highly conductive material. By incorporating AI and tiny graphene electrodes that can monitor and modulate neural activity in real time, Inbrain aims to deliver an unprecedented level of precision in neuromodulation. The platform’s ultra-thin, 10-micrometer implant has been designed to safely interact with brain tissue and provide detailed neural signal processing, potentially improving upon current neuromodulation devices.
The company recently achieved a significant milestone by conducting the world’s first human implantation of its BCI device in a clinical trial at Salford Royal Hospital in the UK. This trial, targeting patients with brain cancer, is testing the safety of the device and exploring the unique advantages of graphene over traditional materials. With FDA Breakthrough Device Designation, Inbrain is positioning itself as a leader in neurotechnology, especially with its subsidiary, INNERVIA Bioelectronics, extending the BCI’s applications to peripheral and systemic diseases.
The recent investment was led by imec.xpand, an investment fund linked to nanoelectronics R&D hub imec, which is helping Inbrain scale up its platform for commercial use. This support not only underlines the promise of Inbrain’s groundbreaking technology but also enhances Europe’s standing in the global BCI industry.
